Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Aptahem

0.30 SEK-9.51 %7/10 17:29
Less than 1K followers

APTA

Spotlight Stock Market

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor views
Compare
-9.51 %
-43.27 %
-50.83 %
-56.62 %
-73.48 %
-75.11 %
-98.22 %
-99.51 %
-99.94 %

Aptahem operates in the pharmaceutical industry. The company develops aptamer-based drugs for the treatment of acute life-threatening conditions where coagulation and inflammation interact in the disease process. The company's lead candidate is being developed as an emergency drug intended to prevent the onset of life-threatening organ and tissue damage in patients suffering from sepsis. A large part of the research is carried out in collaboration with partners in the industry. The company was founded in 2014 and is headquartered in Malmö.

Read more
Market cap
19.13M SEK
Turnover
35.91K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
All
Press releases
3rd party
ShowingAll content types

Financial calendar
26/11
2026

Interim report Q3'26

Regulatory press release2026-10-07 17:42

Aptahem offentliggör preliminärt utfall i företrädesemission

Aptahem
Press release2026-10-02 08:50

Aptahem: Nyhetsbrev oktober 2026

Aptahem
Regulatory press release2026-10-02 08:30

Sista dag för handel med uniträtter i Aptahems företrädesemission

Aptahem

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release2026-09-30 16:13

Aptahems webbinarium "Vägen framåt för Apta-1" nu tillgängligt

Aptahem
Press release2026-09-29 08:35

Aptahems VD interjuad av Finwire

Aptahem
Regulatory press release2026-09-25 15:59

Aptahem har ingått en avsiktsförklaring om kliniskt utvecklingssamarbete med professor Folke Sjöberg

Aptahem
Press release2026-09-25 13:56

Aptahems VD interjuad av Analyst Group

Aptahem
Press release2026-09-25 12:30

Nyemissioner.se: Läs om Aptahem som genomför en företrädesemission om 15,6 MSEK

Aptahem
Press release2026-09-25 09:51

Analyst Group: Analyst Group intervjuar Aptahems VD Mikael Lindstam

Aptahem
Press release2026-09-25 08:30

Analyst Groups Aptahem-analys: Akademiska samarbeten öppnar vägen för Fas 2

Aptahem
Press release2026-09-24 13:15

Analyst Group: Analyst Group kommenterar Aptahem och pågående emission

Aptahem
Regulatory press release2026-09-23 08:30

Idag inleds teckningsperioden i Aptahems företrädesemission av units

Aptahem
Press release2026-09-22 08:30

Aptahem bjuder in till webbinarium den 28 september

Aptahem
Regulatory press release2026-09-16 08:45

Aptahem offentliggör informationsdokument inför företrädesemission av units

Aptahem
Regulatory press release2026-09-14 08:45

Aptahem beslutar om företrädesemission av units om cirka 15,6 MSEK för att accelerera klinisk utveckling och partnerdiskussioner

Aptahem
Press release2026-08-31 08:30

Aptahem: Nyhetsbrev augusti 2026

Aptahem
Regulatory press release2026-08-27 08:02

Aptahems delårsrapport 2026-04-01 till 2026-06-30

Aptahem
Regulatory press release2026-08-25 09:23

Aptahem ingår kommersiellt partneravtal med Jarlen Capital för utlicensiering

Aptahem
Regulatory press release2026-08-25 09:23

Aptahem enters commercial partnership agreement with Jarlen Capital for outlicensing

Aptahem
Press release2026-06-22 08:19

Aptahem: Nyhetsbrev juni 2026

Aptahem